Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom, GSK Pair Up to Create SNP Assay Portfolio

NEW YORK, Aug 29 – Sequenom said Wednesday it had entered an agreement with GlaxoSmithKline to create a SNP assay portfolio that would cover the entire human genome.

"Our immediate goal is to establish a SNP assay portfolio covering all SNPs,” Allen Roses, senior vice president of genetics research at GlaxoSmithKline, said in a statement.

“We are confident that Sequenom can complete a project of this magnitude within our timelines and utilize their technology to enable rapid use of whole genome SNP mapping," he added. 

Under the terms of the deal, GlaxoSmithKline of London will have access to Sequenom’s SNP assay portfolio. The pharmaceutical company then plans to select SNP candidates for genome-wide association studies.

San Diego-based Sequenom said the deal represented a “multimillion dollar agreement” but did not disclose exact terms.

The companies were not immediately available to discuss the announcement.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.